Jacobson & Schmitt Advisors LLC Has $2.39 Million Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Jacobson & Schmitt Advisors LLC decreased its position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) by 13.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,703 shares of the company's stock after selling 6,045 shares during the quarter. Jacobson & Schmitt Advisors LLC's holdings in Verona Pharma PLC American Depositary Share were worth $2,394,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. NBC Securities Inc. bought a new position in Verona Pharma PLC American Depositary Share during the first quarter worth $34,000. Vermillion Wealth Management Inc. bought a new position in Verona Pharma PLC American Depositary Share during the fourth quarter worth $46,000. GF Fund Management CO. LTD. bought a new position in Verona Pharma PLC American Depositary Share during the fourth quarter worth $72,000. Avanza Fonder AB bought a new position in Verona Pharma PLC American Depositary Share during the first quarter worth $100,000. Finally, GAMMA Investing LLC increased its position in Verona Pharma PLC American Depositary Share by 14.0% during the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock worth $117,000 after acquiring an additional 225 shares during the period. Institutional investors own 85.88% of the company's stock.

Insider Buying and Selling

In related news, insider Kathleen A. Rickard sold 114,984 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $8.82, for a total transaction of $1,014,158.88. Following the completion of the sale, the insider directly owned 2,546,472 shares of the company's stock, valued at approximately $22,459,883.04. This represents a 4.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total value of $4,560,000.00. Following the sale, the chief financial officer directly owned 12,278,992 shares of the company's stock, valued at approximately $139,980,508.80. The trade was a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,965,800 shares of company stock valued at $20,056,881. Insiders own 4.80% of the company's stock.

Verona Pharma PLC American Depositary Share Trading Up 0.1%

NASDAQ:VRNA traded up $0.12 on Friday, hitting $104.90. 2,964,026 shares of the stock were exchanged, compared to its average volume of 1,723,026. Verona Pharma PLC American Depositary Share has a 52 week low of $18.51 and a 52 week high of $105.30. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86. The company's 50-day moving average price is $87.55 and its 200 day moving average price is $69.68.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million. On average, equities research analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRNA has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their price target on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. BTIG Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Wolfe Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Truist Financial downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Finally, Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Eleven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.